Vaxart to Present at the 15th Annual World Vaccine Congress in Brussels

SOUTH SAN FRANCISCO, Calif.--()--Vaxart, a privately held, clinical-stage company developing recombinant vaccines that are administered by tablet rather than by injection, today announced that Vaxart founder and chief scientific officer Sean Tucker, PhD, will present clinical data from the company’s influenza tablet vaccine program at the upcoming 15th Annual World Vaccine Congress in Brussels.

Dr. Tucker will discuss the data in his presentation, “High titer neutralizing antibody and potent cellular immune responses to influenza in humans after oral immunization with recombinant adenovirus expressing HA,” on Tuesday, October 14, 2014, at 3:10 p.m. CEST. No webcast will be available.

About Vaxart

Vaxart is a privately owned company developing oral recombinant vaccines based on its proprietary delivery platform. The Vaxart platform is suitable for delivering a wide range of protein vaccine antigens, such as those used in currently marketed influenza, hepatitis B and human papilloma virus (HPV) vaccines. Care Capital is the lead investor in the company and its largest shareholder. For more information, please visit www.vaxart.com.

Contacts

Burns McClellan, on behalf of Vaxart
Justin Jackson, 212-213-0006
jjackson@burnsmc.com

Contacts

Burns McClellan, on behalf of Vaxart
Justin Jackson, 212-213-0006
jjackson@burnsmc.com